Here, we generated two human iPSC lines from ALS patient-specific fibroblasts bearing heterozygous disease-causing mutations (FUS+/G1566A and SOD1+/A272C), and generated their respective isogenic disease-free iPSCs by CRISPR/Cas9 mediated gene correction. The gene discussed is FUS; the disease is amyotrophic lateral sclerosis.